| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 90.5 | 85.9 | 83.9 |
| Other income | 10.0 | 8.8 | 10.6 |
| Total income | 100.6 | 94.7 | 94.5 |
| Profit before exceptional items & tax | 30.1 | 29.6 | 33.9 |
| Profit before tax | 30.1 | 29.6 | 33.9 |
| Net profit | 25.2 | 16.1 | 29.3 |
| Operating margin | 29.9% | 31.3% | 35.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -14.00% |
|---|---|
| Net profit, quarter on quarter | +56.50% |
| Revenue, year on year | +7.90% |
BSE results filing, NSE: NOVARTIND. Figures extracted from the filing.
Novartis India Ltd: key numbers
- Share price
- ₹1,961.40
- Market cap
- ₹4,843 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 49.5×Sector 50.4×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 0.15%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Novartis India Annual General Meeting
Novartis India issued a corrigendum to its 78th AGM notice. This correction clarifies ESOP 2026 scheme details and the company's nature of industry.
Novartis India Earnings Call Transcript: Key Takeaways
Novartis India transition to ChrysCapital ownership (70.68%), pivoting from a partner-led model to a direct, in-house commercial platform focusing on chronic therapies like cardiology and ophthalmology.
Novartis India Investor Presentation: Key Takeaways
Novartis India Limited (NIL) shifts to a direct-to-market model under new ownership by ChrysCapital, acquiring the 'Minipress' brand for ₹1,250 Cr and in-licensing an ophthalmic portfolio.
Novartis India Other Announcement
Novartis India dispatched physical letters with the FY25-26 Annual Report web-link to non-email shareholders per Reg 36(1)(b). This is a routine compliance communication with no financial or business impact.
Novartis India Partnership
Novartis India signed an exclusive distribution deal with Novartis Healthcare for its retina portfolio in India. Upfront consideration of INR 10 Crore expands NIL's ophthalmology presence.
- Value
- ₹10.00 Cr
Novartis India Business Update
Novartis India acquired trademarks 'Minipress' and 'Minipres' from Pfizer for ₹1,250.001 Crore. The IP acquisition strengthens its hypertension and BPH portfolio in India.
- Value
- ₹1,250 Cr